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Abstract
Background: Breast cancer is one of the most common types of cancer in women worldwide. Recent studies have
provided strong support for the cancer stem cell (CSC) hypothesis, which suggests that many cancers, including
breast cancer, are driven by a subpopulation of cells that display stem cell-like properties. The hypothesis that a
subpopulation of circulating tumor cells (CTCs) possesses many CSC-like hallmarks is reinforced by the expression of
related molecular markers between these two cell populations. The aim of this study is to systematically review
primary studies and identify circulating CSC markers in breast cancer patients.
Methods and design: Relevant observational studies evaluating the expression of circulating breast cancer stem cell
markers through October 31, 2016, will be searched in PubMed, SCOPUS, Embase, ISI Web of Science, and Google
Scholar with no restriction on language. Full copies of articles identified by the search and considered to meet the
inclusion criteria will be obtained for data extraction and synthesis. Two quality assessment tools will be used for
evaluating observational studies like case control, which are the Hoy et al. suggested tool and Newcastle-Ottawa Scale
(NOS), respectively. Publication bias will be assessed by funnel plots or Egger’s test (i.e., plots of study results against
precision), and data synthesis will be performed using Stata software (Stata Corp V.12, TX, USA).This systematic review
will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Discussion: Detecting cancer stem cells in blood will help clinicians to monitor cancer patients by obtaining as many
samples as needed with a non-invasive method and in any stages; it is not possible to repeat sampling on working
on tissue samples. By identifying cancer stem cells early in blood, it will be possible to distinguish metastasis in
early stages.
Systematic review registration: CRD42016043810
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Strengths and limitations of this study
 This systematic review will, for the first time,
evaluate circulating cancer stem cell markers in
breast carcinomas without placing restrictions
on language.
 Since there is no specific marker for detecting
circulating cancer stem cells in different subtypes of
breast cancer, we aim to define the best marker(s)
for identification of breast cancer stem cells in
the blood.
 Though the majority of cancer stem cell studies
focus on tissues, identification of cancer stem cells
in the blood can be applicable in diagnosis,
monitoring of patients, and targeted therapy
of tumors.
 The study screening, data extraction, and
assessment of risk of bias of the current study
will be conducted independently by two researchers.
 There is high heterogeneity of cancer stem cell
markers in the circulating blood of breast
cancer patients.
 This review will be limited by the quality and
heterogeneity of the primary studies.
Background
Breast cancer is the sixth most common cause of cancer-
related deaths worldwide and is the second most common
cause of cancer death in women. The incidence of breast
cancer is highest in high-income countries, accounting for
more than half of all breast cancer cases. Although breast
cancer is less common in women living in low-income
countries, the age-adjusted incidence is increasing, and the
rates of increase are often greater in these countries [1].
Circulating tumor cells (CTCs) are a distinct popula-
tion of cancer cells that have detached from the primary
tumor and intravasated into the blood, a necessary step
in forming distant metastases. It is believed that tumor
infiltration of blood vessels at the primary tumor site is
responsible for the dissemination of tumor cells and the
formation of metastatic lesions in distant organs. This
suggests that they may share the hallmarks of cancer
stem cells (CSCs), as CSCs have the ability to give rise to
new tumors. Due to their role in metastasis, CTCs can
be considered the progenitors of relapse and direct con-
tributors to the development of metastasis [2, 3].
Many techniques have been developed and are under
continuous improvement to enhance the efficacy of
CTC isolation and characterization. They have been
proven useful in detecting minor subgroups of cells
present in the primary tumor that may contribute to
treatment resistance or relapse. Hence, detecting and
characterizing CTCs may be a useful tool in treating
solid malignancies [4].
Recent studies have provided strong support for the
cancer stem cell hypothesis, which suggests that many
cancers, including breast cancer, are driven by a subpop-
ulation of cells that display stem cell properties. These
cells may mediate metastasis and, by virtue of their
relative resistance to chemotherapy and radiation, con-
tribute to treatment relapse [5].
Various markers are used to identify the unique sub-
population of breast cancer cells with stem cell proper-
ties. Whether these markers are expressed in all breast
cancers, identify the same population of cells, or equate
to therapeutic response is controversial. The relationship
of breast cancer stem cells with clinical parameters will
require the identification of specific markers for the
individual cancer patient [6].
CTCs and CSCs have been proposed as valuable tools
for the detection and characterization of disease and
individualization of therapy for multiple solid tumors. A
focused and prospective validation of the clinical utility
of detecting these cells is still needed, but results suggest
that they may add great benefit for the early detection
and personalization of therapy [7].
One well-defined method for the identification of
putative breast cancer stem cells (BCSCs) is flow cytometry
[8]. For the first time, breast cancer-initiating cells were
isolated based on the expression of unique cell surface an-
tigens, which include epithelial specific antigen (ESA) and
CD44, but not CD24 [9]. Subsequent studies demonstrated
that the CD44+ and CD24− phenotype can define a popula-
tion enriched for BCSCs. Other cell surface markers, like
CD49f and CD133, can, when combined with CD44+ and
CD24−, be used to identify BCSCs in different breast can-
cer subtypes [10, 11]. BCSCs can also be isolated using the
Aldefluor assay based on aldehyde dehydrogenase (ALDH)
activity [12]. The EpCAM+, CD24−, CD44+, and ALDH+
populations across different subtypes of breast cancers
represent anatomically distinct BCSCs with respective
EMT (epithelial-to-mesenchymal transition) and MET
(mesenchymal-to-epithelial transition) gene expression
profiles. These populations dynamically transition be-
tween the mesenchymal and epithelial states reflective of
their normal counterparts in the mammary epithelial
hierarchy [13].
Although identification of these markers in tissue may
be meaningful clinically, in practice, it is not possible to
take repeated tissue samples from the breast. However,
it is possible to take peripheral blood samples multiple
times. Due to the high heterogeneity of breast cancers
and the diversity of BCSC markers, many studies suggest
using a panel of markers for the identification of BCSCs.
However, previous attempts to discover appropriate
BCSC markers have not been successful.
In previous studies, different markers of tumor cells,
including EPCAM, CD44, CD24, ALDH1, CD133, and
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PIWIL2, found in the blood of breast cancer patients were
evaluated to determine whether it was possible to use circu-
lating BCSCs for patient monitoring, prognosis, diagnosis,
and response to therapy [14–23]. To date, several re-
searchers have published their data on stem cell markers in
CTCs in patients with breast cancer, but there is no system-
atic review on identifying markers of circulating BCSCs.
Methods/design
Objectives
The objective of this review is to provide a systematic re-
view of primary studies to identify the BCSC markers in
the circulating blood of breast cancer patients. This re-
view will complement the findings of an existing review
published in 2015 [24].
Review questions
This review of studies should address the following
questions:
1. Establish the existence of circulating CSC markers in
patients with breast carcinomas
2. Establish the identification of circulating CSC
markers in patients with breast carcinomas
Study design
This review protocol has been published in the PROS-
PERO international prospective register of systematic re-
views (http://www.crd.york.ac.uk/PROSPERO), registration
number CRD42016043810.
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses for Protocols 2015 (PRISMA-P 2015)
have been used for preparing and reporting the protocol
of this systematic review [25]. The methods adopted for
this systematic review have been developed in accordance
with the guidelines detailed on the PRISMA checklist, and
the PRISMA flow diagram will be used to describe the
flow of information through the different phases of the
systematic review (Additional file 1) [26].
Criteria for considering studies for the review
Inclusion criteria
Observational studies (cross-sectional, case-control, and
cohort) which assessed circulating CSC markers and iden-
tified these markers in breast carcinomas based on defined
methods will be included. These methods which are used
for CSC identification and isolation are as follows:
1. Magnetic-activated cell sorting (MACS) is a method
for separation of various cell populations depending
on their surface antigens (CD molecules). In this
method, the super paramagnetic nanoparticles are
used to tag the targeted cells in order to capture
them inside the column.
2. Flow cytometry is a laser- or impedance-based,
biophysical technology employed in cell counting
and biomarker detection which allows an individual
characterization of rare cells like CTCs. It is used for
immunophenotyping the cells. It is predominantly
used to measure fluorescence intensity produced
by fluorescent-labeled antibodies detecting proteins
or ligands that bind to specific cell-associated
molecules.
3. Fluorescence-activated cell sorting (FACS) is a
specialized type of flow cytometry. It provides a
method for sorting a heterogeneous mixture of
biological cells into two or more containers, one cell
at a time, based upon the attached conjugated
antibody to its surface emits specific fluorescent
lights which is used for characterization of each cell.
It is a useful scientific instrument as it provides fast,
objective, and quantitative recording of fluorescent
signals from individual cells as well as physical
separation of cells of particular interest.
4. Reverse transcription polymerase chain reaction
(RT-PCR) is a variant of polymerase chain reaction
(PCR) and is a technique commonly used in
molecular biology to detect RNA expression and to
measure the quality of the gene expression in cells.
5. Real-time polymerase chain reaction (real-time
PCR), also known as quantitative polymerase chain
reaction (qPCR). It monitors the amplification of a
targeted DNA molecule during the PCR, i.e., in
real-time and not at its end, as in conventional
PCR. Real-time PCR can be used quantitatively
(quantitative real-time PCR) and semi-quantitatively,
i.e., above/below a certain amount of DNA
molecules (semi quantitative real-time PCR).
6. Filtration is used to enrich CTC which is solely
based on the size of the cells.
7. Density gradient centrifugation and
immunocytochemistry is one way to enrich
disseminated tumor cells. Mononuclear cells are
isolated using Ficoll and are subsequently spun on
glass slides. Visualization of the tumor cells beside
the leukocytes is effected by means of
immunocytochemistry.
8. Chip based methods:
a. Microfluidics, immobilization and in situ
hybridization (ISH) uses special chips combining
microfluidics and immobilization of CTCs by
binding of specific antibodies. The latter chip is
used to establish RNA ISH assay to detect and
quantify CTCs. ISH is a type of hybridization that
uses a labeled complementary DNA, RNA, or
modified nucleic acids strand (i.e., probe) to
localize a specific DNA or RNA sequence in cells
(e.g., CTC-chip, Herringbone Chip).
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b. A novel chip-based platform using size-based
separation separates nucleated cells from whole
blood by using size-based separation, then aligns
cells in a microfluidic channel using inertial
focusing, and subsequently isolates CTCs by
means of negative selection (leukocytes depletion)
using microfluidic magnetophoresis. This method
significantly reduces contamination of the isolated
CTCs with undesired hematopoietic cells as well
as includes CTCs that have undergone epithelial
to mesenchymal transition (EMT) and thus lost
epithelial traits.
Participants
Adult patients with breast cancer, any subtype, will
be included.
Outcomes
The primary outcome will be the expression pattern of cir-
culating CSC markers in breast carcinomas including
EPCAM, CD44, CD24, ALDH1, CD133, and PIWIL2. The
secondary outcome will be expression pattern of circulating
CSC markers in individual subtypes of breast carcinomas.
Types of studies to be excluded
Studies assessing animal models, reviews, letters, edito-
rials, case reports, and case series studies will be excluded.
Search methods for identification of studies
Electronic searches
To identify the relevant studies, we will search the data-
bases PubMed, Web of Science, Embase, Scopus, and
Google Scholar (up to October 2016).
PUBMED search strategy
In the PubMed database, the search syntax will be:
Breast AND (Cancer OR Neoplasm OR Carcinoma OR
Tumor OR Tumour OR Cancers OR Neoplasms) AND
circulating AND (“tumor cell” OR “cancer cell” OR
“cancer stem cell” OR “initiating stem cell” OR “tumor
initiating cell”) AND (“stemness marker” OR marker OR
“surface marker”). The search syntax will be modified in
other databases.
Data extraction (selection and coding)
Two reviewers (M. Mansoori and L. Janani) will
independently extract the following information from
each study:
1. Study characteristics (author, year of publication,
language of publication, country, study design, setting,
locations, criteria for sample selection and sample size,
diagnostic criteria, outcomes measured, and patient
enrolment strategies)
2. Participants’ characteristics (age, gender)
3. Frequency estimates of cancer stem cell marker ex-
pression on the surface of circulating tumor cells.
Discrepancies between the two reviewers will be resolved
by discussion. An independent investigator will be con-
sulted to reach a consensus where there is uncertainty
or disagreement between the reviewers.
Risk of bias (quality) assessment
Two reviewers, LJ and MM, will independently assess
the methodological quality of primary studies by a qual-
ity assessment tool developed by Hoy et al. [27] and
adapted by Werfalli et al. [28]. It will be applied and fur-
ther adapted, if necessary, to all screened full-text arti-
cles in order to assess study quality. The defined
questions will be answered and the score of each article
will be calculated using this assessment tool. Studies will
be graded as low risk, moderate risk, and high risk for
scores of 6, 6–8, and > 8, respectively. The Newcastle-
Ottawa Scale (NOS) will be used to assess the quality of
studies, if the case-control primary studies will be in-
cluded in the systematic review. This tool was developed
as a collaboration between the University of Newcastle,
Australia, and the University of Ottawa, Canada, using a
Delphi process to define variables for data extraction.
Using the tool, each study is judged on eight items, cate-
gorized into three groups: the selection of the study
groups, the comparability of the groups, and the ascer-
tainment of either the exposure or outcome of interest
for case-control or cohort studies, respectively [29]. An
independent investigator will be consulted to reach a
consensus where there is uncertainty or disagreement
between the reviewers.
Strategy for data synthesis
We will review and present all included studies in two
separate tables. The first table will provide details on
study quality according to the abovementioned tool. The
other table will include study design, patient demo-
graphic, and identification of circulating CSC markers in
patients with breast carcinomas. The guidelines sug-
gested by the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2008) will be used for
appropriate statistical analysis. Data will be analyzed
using Stata software (Stata Corp V.12, TX, USA).
Initially, the data will be analyzed using a narrative
method. For studies with control group, we planned to
use meta-analysis to combine the results. We will
present dichotomous outcomes as odds ratios with 95%
confidence intervals (CI). Heterogeneity will be evalu-
ated to determine the extent of variation in effect
estimates due to heterogeneity rather than chance. The
heterogeneity among the primary studies will be evalu-
ated by a visual inspection of the forest plots, χ2 test
(with significance defined at α-level of 10%) and I2
Mansoori et al. Systematic Reviews  (2017) 6:262 Page 4 of 6
statistic. Categories of heterogeneity will be ≤ 25% low,
26–50% moderate, 51–75% substantial, and ≥ 76% as
considerable heterogeneity as defined by Higgins. For
low and moderate level of heterogeneity, we will use
fixed-effect model, and a random-effects model will be
used in situations where the level of heterogeneity is
substantial. If there will be a considerable level of
heterogeneity and the number of studies will be enough,
we will try to identify potential sources of heterogeneity
by investigating individual studies and using meta-
regression. Publication bias will be assessed by funnel
plots and Egger’s test. Sensitivity analysis will be per-
formed according to quality of the studies and differ-
ences in countries when appropriate.
Analysis of subgroups or subsets
Subgroup analysis will also be used when appropriate (for
example, according to cancer subtypes and age groups).
Discussion
This review will summarize the data around different
markers of circulating cancer stem cell in breast carcin-
omas. We will report the results of our review in agree-
ment with the PRISMA statement (PRISMA-P 2015
checklist). We aim to introduce marker(s) to best detect
breast cancer stem cells in circulation since there is no
existing any other similar study. Detecting cancer stem
cells in blood will help clinicians to monitor cancer pa-
tients by obtaining as many samples as needed with a
non-invasive method and in any stages; it is not possible
to repeat sampling on working on tissue samples. By iden-
tifying cancer stem cells early in blood, it will be possible
to distinguish metastasis in early stages.
To our knowledge, this review will be the first of its
kind to address this topic. The results of this study can
be applicable in diagnosis, monitoring of patients, and
targeted therapy of tumors for breast cancer patients.
Additional file
Additional file 1: PRISMA-P (Preferred Reporting Items for Systematic
Review and Meta-Analysis Protocols) 2015 checklist. (DOC 85 kb)
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